Mucosal Immune-enhancing Delivery System for HIV vaccines
HIV 疫苗的粘膜免疫增强输送系统
基本信息
- 批准号:7756171
- 负责人:
- 金额:$ 14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-21 至 2012-06-30
- 项目状态:已结题
- 来源:
- 关键词:AdjuvantAnti-Inflammatory AgentsAnti-inflammatoryAntibodiesAntibody FormationAntigen-Presenting CellsAntigensB-LymphocytesBiological AssayCatechinCell LineCellsCervical lymph node groupCommon iliac lymph nodeCountryCutaneous AdministrationCytotoxic T-LymphocytesDataDermalDeveloped CountriesDeveloping CountriesDoctor of PhilosophyDrug FormulationsEffectivenessEnzyme-Linked Immunosorbent AssayEpithelialEpithelial CellsEquilibriumFaceFeesFemaleFlavonoidsGenerationsGenital systemGenitourinary systemGoalsHIVHIV Envelope Protein gp120HIV InfectionsHIV envelope proteinHIV vaccineHIV-1HourHumanIgG1ImmuneImmune responseImmunityImmunizationImmunoglobulin AImmunoglobulin GImmunoglobulin MImmunosuppressive AgentsIn VitroInbred BALB C MiceIndividualInfectionInflammatoryInstitutionInterleukin-10Interleukin-12Interleukin-5JuglansKnowledgeLeadLicensingMacaca mulattaMarketingMeasurementMeasuresMemoryMucous MembraneMusNosePhasePrincipal InvestigatorProductionProteinsResearchRouteSeriesSerumSiteSmall Business Innovation Research GrantSocietiesSpleenStagingSuspension substanceSuspensionsSystemT-LymphocyteTechnologyTestingThailandTimeTimeLineTissuesToxic effectTranslatingUgandaVaccinatedVaccinationVaccinesVaginaVitamin Abasechemokinecytokinecytotoxicdesignenzyme linked immunospot assaygastrointestinalimmunogenicityin vivomacrophagemucosal sitemustard oilneutralizing antibodynovelprophylacticprotective efficacypublic health relevancerespiratoryresponsesimian human immunodeficiency virustherapeutic vaccinetransmission processvaccine deliveryvaccine development
项目摘要
DESCRIPTION (provided by applicant): Despite close to 40 million HIV-infected individuals worldwide and millions of new infections each year, intense research in the field of HIV vaccine development has not yet lead to a licensed prophylactic or therapeutic vaccine. Regardless of the route of infection, HIV targets mucosal cells of the gastrointestinal, respiratory and genitourinary tracts, at both early and late stages of infection. HIV transmission through the female genital tract (FGT) remains a major route of infection. Thus, generation of immune responses at this mucosal portal of HIV entry, as well as systemic sites would be advantageous. Induction of immune responses at mucosal sites requires safe and effective immune enhancing delivery systems and adjuvants, which currently do not exist in licensed form mainly due to their toxicity issues. In phase I of this proposal, we will test in mice the effectiveness of a novel and safe formulation designated mucosal immune enhancing delivery system (MIDS) for mucosal (intra-nasal) and systemic (intra-dermal) administration of an HIV-envelope protein with the goal of inducing immunity in both FGT and systemic tissues. The specific aims will include first optimization of the MIDS formulations and induction of in vitro innate responses in epithelial and antigen-presenting cells (APC), followed by in vivo induction in mice of mucosal and systemic innate and adaptive responses by antigen-presenting, B and T cells, including regulatory (Treg), helper (TH) and cytotoxic (CTL). In phase II, we will test the immunogenicity and protective efficacy of immunizations with MIDS with HIVenv proteins in female rhesus macaques followed by intra-vaginal challenge with SHIV. PUBLIC HEALTH RELEVANCE: Currently, there are no licensed vaccines against infections with HIV. This project pertains to designing a novel, safe and effective Mucosal Immune-enhancing Delivery System for HIV vaccine development that can protect the public against new infections with the HIV virus.
描述(由申请人提供):尽管全世界有近4000万HIV感染者,每年有数百万新感染者,但HIV疫苗开发领域的深入研究尚未导致获得许可的预防性或治疗性疫苗。无论感染途径如何,艾滋病毒在感染的早期和晚期都以胃肠道、呼吸道和泌尿生殖道的粘膜细胞为目标。通过女性生殖道传播艾滋病毒仍然是主要的感染途径。因此,在HIV进入的粘膜入口以及全身部位产生免疫应答将是有利的。在粘膜部位诱导免疫应答需要安全有效的免疫增强递送系统和佐剂,主要由于它们的毒性问题,它们目前不以许可的形式存在。在本提案的I期,我们将在小鼠中测试一种新型安全制剂的有效性,该制剂被称为粘膜免疫增强递送系统(MIDS),用于HIV包膜蛋白的粘膜(鼻内)和全身(皮内)给药,目的是诱导FGT和全身组织的免疫力。具体目标将包括首先优化MIDS制剂和诱导上皮细胞和抗原呈递细胞(APC)中的体外先天性应答,然后通过抗原呈递、B和T细胞(包括调节性(Treg)、辅助性(TH)和细胞毒性(CTL))在小鼠中体内诱导粘膜和全身先天性和适应性应答。在第II阶段,我们将在雌性恒河猴中测试用具有HIVenv蛋白的MIDS免疫,然后用SHIV阴道内攻击的免疫原性和保护效力。公共卫生相关性:目前,没有获得许可的预防艾滋病毒感染的疫苗。该项目涉及设计一种新型,安全和有效的Muclidase免疫增强递送系统用于HIV疫苗开发,可以保护公众免受HIV病毒的新感染。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael Sejr Vajdy其他文献
Michael Sejr Vajdy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael Sejr Vajdy', 18)}}的其他基金
Mucosal Immune-enhancing Delivery System for HIV vaccines
HIV 疫苗的粘膜免疫增强输送系统
- 批准号:
8143122 - 财政年份:2009
- 资助金额:
$ 14万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 14万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 14万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 14万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 14万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 14万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 14万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 14万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 14万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 14万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 14万 - 项目类别: